Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Mineralys Therapeutics, Inc. (MLYS : NSDQ)

• Company Description    Mineralys Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. Mineralys Therapeutics Inc. is based in RADNOR, Pa. Number of Employees: 51

• Price / Volume Information    Yesterday's Closing Price: $14.64 Daily Weekly Monthly 20 Day Moving Average: 863,700 shares Shares Outstanding: 65.18 (millions) Market Capitalization: $954.17 (millions) Beta: -0.30 52 Week High: $18.38 52 Week Low: $8.24 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -1.88% -5.55% 12 Week 9.66% -7.76% Year To Date 18.93% 11.38%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 150 N. RADNOR CHESTER ROAD SUITE F200 - RADNOR,PA 19087 USA ph: 888-378-6240 fax: - investorrelations@mineralystx.com http://www.mineralystx.com

• General Corporate Information    Officers Jon Congleton - Chief Executive Officer and Director Glenn Sblendorio - Chairman Adam Levy - Chief Financial Officer and Secretary Srinivas Akkaraju - Director Derek DiRocco - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 603170101 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/25 Next Expected EPS Date: 08/12/25 Share - Related Items Shares Outstanding: 65.18 Most Recent Split Date: (:1) Beta: -0.30 Market Capitalization: $954.17 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.77 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-3.31 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 5.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/12/25

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 2.78 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: -12.86% vs. Previous Quarter: 19.39% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 06/30/25 - - 03/31/25 - -71.15 12/31/24 - -67.97 ROA 06/30/25 - - 03/31/25 - -65.71 12/31/24 - -62.40 Current Ratio 06/30/25 - - 03/31/25 - 26.48 12/31/24 - 14.02 Quick Ratio 06/30/25 - - 03/31/25 - 26.48 12/31/24 - 14.02 Operating Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Net Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Pre-Tax Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Book Value 06/30/25 - - 03/31/25 - 5.26 12/31/24 - 3.84 Inventory Turnover 06/30/25 - - 03/31/25 - - 12/31/24 - - Debt-to-Equity 06/30/25 - - 03/31/25 - 0.00 12/31/24 - 0.00 Debt-to-Capital 06/30/25 - - 03/31/25 - 0.00 12/31/24 - 0.00

Powered by Zacks Investment Research ©